ストックスクリーナーアプリを入手
20.95
5.28%
1.0568
Ideaya Biosciences Inc (IDYA) 最新ニュース
IDEAYA Biosciences CEO Set for Major Healthcare Conference Double-Header: Jefferies and Goldman Sachs - Stock Titan
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Eastern Progress
Ideaya Biosciences announces inducement grants under Nasdaq listing rule - TipRanks
IDEAYA Biosciences (IDYA) Grants Stock Options to New Employees | IDYA Stock News - GuruFocus
IDEAYA Biosciences Expands Oncology Team with 664,600 Share Grant Worth Over $13M - Stock Titan
IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Shares Purchased by Nuveen Asset Management LLC - Defense World
IDEAYA Biosciences (NASDAQ:IDYA) Price Target Raised to $66.00 - Defense World
IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Receives $54.27 Consensus PT from Brokerages - Defense World
(IDYA) Proactive Strategies - news.stocktradersdaily.com
JP Morgan Raises Price Target for IDEAYA Biosciences (IDYA) | ID - GuruFocus
IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Shares Acquired by Ameriprise Financial Inc. - Defense World
BNP Paribas Financial Markets Buys 10,543 Shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA) - Defense World
Jane Street Group LLC Reduces Stake in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) - Defense World
Bank of America Corp DE Acquires 41,390 Shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA) - Defense World
January 2026 Options Now Available For IDEAYA Biosciences - Nasdaq
Ideaya Biosciences: Value Beyond Darovasertib With ADC Program IDE849 (NASDAQ:IDYA) - Seeking Alpha
(IDYA) Investment Analysis - news.stocktradersdaily.com
FY2025 EPS Estimates for IDYA Cut by Cantor Fitzgerald - Defense World
Stifel Financial Corp Sells 3,834 Shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA) - Defense World
Dimensional Fund Advisors LP Has $8.91 Million Stock Holdings in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) - Defense World
16,769 Shares in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Acquired by Raymond James Financial Inc. - Defense World
Brokers Issue Forecasts for IDYA Q2 Earnings - Defense World
Leerink Partnrs Has Bullish Estimate for IDYA Q2 Earnings - Defense World
IDEAYA Biosciences Receives Fast Track Designation for IDE161 in a Second Indication for the Treatment of Pretreated, Advanced or Metastatic HR+, Her2-, BRCA1/2 mutant Breast Cancer - Barchart.com
Ideaya Biosciences (IDYA) Faces Market Reaction Following FDA Le - GuruFocus
IDEAYA Biosciences Reports Q1 2025 Financial Results - TipRanks
IDEAYA Biosciences (NASDAQ:IDYA) Shares Down 10.2% After Earnings Miss - Defense World
IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Shares Bought by Mariner LLC - Defense World
IDEAYA Biosciences, Inc. Reports First Quarter 2025 Financial Results and Provides Business Update - The Malaysian Reserve
IDEAYA Gets FDA Clearance to Initiate Clinical Trial of Antibody Drug Conjugate Program in Solid Tumors - marketscreener.com
IDEAYA Biosciences Posts Q1 Net Loss; Cash Runway Extended Through 2029 - marketscreener.com
IDEAYA gets approval to begin trial for its antibody drug conjugate in solid tumors - Seeking Alpha
IDEAYA Biosciences Announces US FDA IND-Clearance for IDE849, a - GuruFocus
Ideaya Biosciences (IDYA) Achieves Major Milestones in Oncology Programs | IDYA Stock News - GuruFocus
Ideaya Biosciences (IDYA) Advances with FDA Approval for IDE849 Trial | IDYA Stock News - GuruFocus
IDEAYA Biosciences Announces US FDA IND-Clearance For IDE849, A Potential First-In-Class DLL3 TOP1 ADC, For A Phase 1 Study In Solid Tumors - marketscreener.com
FDA clears IDEAYA’s Phase 1 trial for new cancer drug By Investing.com - Investing.com South Africa
FDA clears IDEAYA’s Phase 1 trial for new cancer drug - Investing.com
IDEAYA Biosciences Announces US FDA IND-Clearance for IDE849, a Potential First-in-Class DLL3 TOP1 ADC, for a Phase 1 Study in Solid Tumors - marketscreener.com
IDEAYA Biosciences Announces US FDA IND-Clearance for IDE849, a Potential First-in-Class DLL3 TOP1 ADC, for a Phase 1 Study in Solid Tumors – Company Announcement - Financial Times
IDEAYA Receives Fast Track Designation for Potential First-in-Class PARG Inhibitor, IDE161, for Treatment of Pretreated, Platinum-Resistant Advanced or Metastatic Ovarian Cancer Patients having tumors with BRCA1/2 Mutations - Barchart.com
IDEAYA Biosciences Announces Phase 2 Expansion of Darovasertib and Crizotinib Combination in GNAQ/11 Metastatic Cutaneous Melanoma - Barchart.com
Why IDEAYA Biosciences, Inc. (IDYA) is Among the Best Small Cap Stocks to Buy with the Biggest Upside Potential - Insider Monkey
IDEAYA Biosciences (IDYA) to Release Quarterly Earnings on Tuesday - Defense World
Top 11 Small Cap Stocks to Buy with Biggest Upside Potential - Insider Monkey
Trading (IDYA) With Integrated Risk Controls - news.stocktradersdaily.com
Invesco Ltd. Has $1.46 Million Holdings in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) - Defense World
Nothing is Better Than Ideaya Biosciences Inc (IDYA) stock at the moment - Sete News
Ideaya Biosciences Inc (IDYA)’s Ratio Roundup: Key Metrics for Trailing Twelve Months - DWinneX
IDYA (Ideaya Biosciences Inc) has impressive results - uspostnews.com
Investing in Ideaya Biosciences Inc (IDYA): What You Must Know - knoxdaily.com
IDEAYA Biosciences to Participate in Upcoming May 2025 Investor Relations Events - GuruFocus
Ideaya Biosciences Inc (NASDAQ: IDYA) Stock Forecast: An Analysis - Marketing Sentinel
IDYAIdeaya Biosciences Latest Stock News & Market Updates - Stock Titan
Envestnet Asset Management Inc. Sells 11,342 Shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA) - Defense World
IDEAYA Biosciences Grants Stock Options To New Employees Under 2023 Inducement Plan - Nasdaq
New PARG inhibitors disclosed in Ideaya patent - BioWorld MedTech
IDEAYA Biosciences Expands Team with Major Equity Grants: 185,400 Shares Awarded to Key New Talent - Stock Titan
Ideaya Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - marketscreener.com
Analysts review Ideaya Biosciences Inc’s rating - knoxdaily.com
Ideaya Biosciences Inc (IDYA) shows promising results - uspostnews.com
Wells Fargo & Company MN Trims Stake in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) - Defense World
1.76%
0.89%
大文字化:
|
ボリューム (24 時間):